Abstract:Introduction Among various lupus renal vascular changes, thrombotic microangiopathy (TMA) presented with the most severe clinical manifestations and high mortality. The pathogenesis of TMA in systemic lupus erythematosus (SLE) was complicated. The aim of this study was to assess clinical manifestations, laboratory characteristics, pathological features and risk factors for clinical outcomes of lupus nephritis patients co-existing with renal TMA in a large cohort in China. Methods Clinical and renal histopathological data of 148 patients with biopsy-proven lupus nephritis were retrospectively analyzed. Serum complement factor H, A Disintegrin and Metalloprotease with Thrombospondin type I repeats 13 (ADAMTS-13) activity, antiphospholipid antibodies and C4d deposition on renal vessels were further detected and analyzed. Results In the 148 patients with lupus nephritis, 36 patients were diagnosed as co-existing with renal TMA based on pathological diagnosis. Among the 36 TMA patients, their clinical diagnoses of renal TMA were as followings: 2 patients combining with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 2 patients combining with anti-phospholipid syndrome, 2 patients with malignant hypertension, 1 patient with scleroderma and the other 29 patients presenting with isolated renal TMA. Compared with the non-renal TMA group, patients with renal TMA had significantly higher urine protein (7.09 ± 4.64 vs. 4.75 ± 3.13 g/24h, P = 0.007) and serum creatinine (159, 86 to 215 vs. 81, 68 to 112 μmol/l, P <0.001), higher scores of total activity indices (AI) ( P <0.001), endocapillary hypercellularity ( P <0.001), subendothelial hyaline deposits ( P = 0.003), interstitial inflammation ( P = 0.005), glomerular leukocyte infiltration ( P = 0.006), total chronicity indices (CI) ( P = 0.033), tubular atrophy ( P = 0.004) and interstitial fibrosis ( P = 0.018). Patients with renal TMA presented with poorer renal outcome ( P = 0.005) compared with the non-TMA group. Renal TMA (hazard ratio (HR): 2.772, 95% confidence interval: 1.009 to 7.617, P = 0.048) was an independent risk factor for renal outcome in patients with lupus nephritis. The renal outcome was poorer for those with both C4d deposition and decreased serum complement factor H in the TMA group ( P = 0.007). Conclusions There were various causes of renal TMA in lupus nephritis. Complement over-activation via both classical and alternative pathways might play an important role in the pathogenesis of renal TMA in lupus nephritis.

TMA Secondary to SLE: Rituximab Improves Overall but Not Renal Survival

Rituximab As Maintenance Therapy Following Remission Induction in Relapsing or Refractory Systemic Lupus Erythematosus.

Efficacy of individualized rituximab as the rescue therapy for active lupus nephritis with acute kidney injury

Clinicopathological Features and Outcomes of SLE Patients with Renal Injury Characterised by Thrombotic Microangiopathy.

Efficacy and Safety of Rituximab Therapy for Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment

Thrombocytopenia Is an Independent Risk Factor for the Prognosis of Thrombotic Microangiopathy in Chinese Patients With Systemic Lupus Erythematosus

Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.

Efficacy of rituximab in patients with refractory severe systemic lupus erythematosus

The Spectrum of Renal Thrombotic Microangiopathy in Lupus Nephritis

The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis

Efficacy And Safety Of Rituximab In Systemic Lupus Erythematosus And Sjogren Syndrome Patients With Refractory Thrombocytopenia A Retrospective Study Of 21 Cases

[The 476th Case: Skin Rash, Edema, Thrombocytopenia and Anemia].

Plasmapheresis is Associated with Better Renal Outcomes in Lupus Nephritis Patients with Thrombotic Microangiopathy

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus

Rituximab in systemic lupus erythematosus and lupus nephritis

Rituximab in patients with membranous nephropathy and kidney insufficiency

Clinical Profile, Treatment and Outcome of Thrombotic Thrombocytopenia Purpura (TTP) in Rituximab Era- an Experience from Tertiary Care Centre from North India

Rituximab in the Treatment of Severe Lupus Myelopathy